CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
7.22
-0.57 (-7.32%)
At close: May 30, 2025, 4:00 PM
7.13
-0.09 (-1.25%)
After-hours: May 30, 2025, 6:58 PM EDT
CervoMed Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for CervoMed stock ranges from a low of $10 to a high of $63. The average analyst price target of $25.57 forecasts a 254.16% increase in the stock price over the next year.
Price Target: $25.57 (+254.16%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CervoMed stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 3 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +38.50% | May 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $14 → $15 | Strong Buy | Maintains | $14 → $15 | +107.76% | May 12, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +38.50% | Mar 26, 2025 |
| Roth MKM | Roth MKM | Strong Buy Maintains $15 → $20 | Strong Buy | Maintains | $15 → $20 | +177.01% | Mar 18, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $21 | Strong Buy | Maintains | $12 → $21 | +190.86% | Mar 18, 2025 |
Financial Forecast
Revenue This Year
5.67M
from 9.74M
Decreased by -41.79%
Revenue Next Year
n/a
from 5.67M
EPS This Year
-2.08
from -2.02
EPS Next Year
-1.77
from -2.08
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.3M | n/a | n/a | ||
| Avg | 5.7M | n/a | n/a | ||
| Low | 2.9M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.3% | - | - | ||
| Avg | -41.8% | - | - | ||
| Low | -69.8% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.35 | -0.63 | -0.36 | ||
| Avg | -2.08 | -1.77 | -1.72 | ||
| Low | -2.52 | -2.76 | -3.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.